Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Income towards Parent Company (2020 - 2023)

Historic Income towards Parent Company for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to -$21.1 million.

  • Terns Pharmaceuticals' Income towards Parent Company fell 3127.45% to -$21.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$90.3 million, marking a year-over-year decrease of 4900.8%. This contributed to the annual value of -$89.6 million for FY2024, which is 78.76% up from last year.
  • As of Q4 2023, Terns Pharmaceuticals' Income towards Parent Company stood at -$21.1 million, which was down 3127.45% from -$29.8 million recorded in Q3 2023.
  • In the past 5 years, Terns Pharmaceuticals' Income towards Parent Company ranged from a high of -$9.2 million in Q1 2020 and a low of -$29.8 million during Q3 2023
  • Moreover, its 4-year median value for Income towards Parent Company was -$13.9 million (2022), whereas its average is -$15.2 million.
  • As far as peak fluctuations go, Terns Pharmaceuticals' Income towards Parent Company crashed by 210.51% in 2021, and later plummeted by 7697.38% in 2023.
  • Terns Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$11.1 million in 2020, then dropped by 29.0% to -$14.3 million in 2021, then fell by 12.07% to -$16.1 million in 2022, then plummeted by 31.27% to -$21.1 million in 2023.
  • Its Income towards Parent Company stands at -$21.1 million for Q4 2023, versus -$29.8 million for Q3 2023 and -$17.9 million for Q2 2023.